DOP2013000249A - Monohidrato de derivados de aza-adamantano - Google Patents

Monohidrato de derivados de aza-adamantano

Info

Publication number
DOP2013000249A
DOP2013000249A DO2013000249A DO2013000249A DOP2013000249A DO P2013000249 A DOP2013000249 A DO P2013000249A DO 2013000249 A DO2013000249 A DO 2013000249A DO 2013000249 A DO2013000249 A DO 2013000249A DO P2013000249 A DOP2013000249 A DO P2013000249A
Authority
DO
Dominican Republic
Prior art keywords
monohidrate
aza
adamantan
derivatives
adamantan derivatives
Prior art date
Application number
DO2013000249A
Other languages
English (en)
Inventor
Shuang Chen
James J Napier
Geoff G Z Zhang
Paul J Brackemeyer
Original Assignee
Abbvie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44736085&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DOP2013000249(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abbvie Inc filed Critical Abbvie Inc
Publication of DOP2013000249A publication Critical patent/DOP2013000249A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/14—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing 9-azabicyclo [3.3.1] nonane ring systems, e.g. granatane, 2-aza-adamantane; Cyclic acetals thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Addiction (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Gynecology & Obstetrics (AREA)
  • Oncology (AREA)
  • Psychology (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)

Abstract

Forma cristalina monohidrato del citrato diácido de (4s)-4-(5-fenil-1,3,4- tiadiazol-2-iloxi)-1-azatriciclo[3.3.1.13,7]decano, composiciones que comprenden dicho compuesto y un proceso para preparar el compuesto.
DO2013000249A 2010-09-23 2013-07-17 Monohidrato de derivados de aza-adamantano DOP2013000249A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US38567410P 2010-09-23 2010-09-23

Publications (1)

Publication Number Publication Date
DOP2013000249A true DOP2013000249A (es) 2014-01-15

Family

ID=44736085

Family Applications (2)

Application Number Title Priority Date Filing Date
DO2013000064A DOP2013000064A (es) 2010-09-23 2013-03-22 Monohidrato de derivados de aza-adamantano
DO2013000249A DOP2013000249A (es) 2010-09-23 2013-07-17 Monohidrato de derivados de aza-adamantano

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DO2013000064A DOP2013000064A (es) 2010-09-23 2013-03-22 Monohidrato de derivados de aza-adamantano

Country Status (24)

Country Link
US (2) US9464078B2 (es)
EP (1) EP2619205B1 (es)
JP (2) JP2013537912A (es)
KR (1) KR20130108586A (es)
CN (2) CN103180321A (es)
AR (1) AR083100A1 (es)
AU (1) AU2011305462B2 (es)
BR (2) BR112013005434A2 (es)
CA (1) CA2809675A1 (es)
CL (2) CL2013000756A1 (es)
CO (1) CO6720965A2 (es)
CR (2) CR20130169A (es)
DO (2) DOP2013000064A (es)
EC (1) ECSP13012575A (es)
GT (1) GT201300064A (es)
MX (1) MX2013003344A (es)
NZ (2) NZ609761A (es)
PE (1) PE20131394A1 (es)
RU (2) RU2016105706A (es)
SG (2) SG2014013460A (es)
TW (2) TW201212914A (es)
UA (1) UA110802C2 (es)
UY (1) UY33628A (es)
WO (1) WO2012040404A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8314119B2 (en) 2006-11-06 2012-11-20 Abbvie Inc. Azaadamantane derivatives and methods of use
KR20130108586A (ko) 2010-09-23 2013-10-04 애브비 인코포레이티드 아자아다만탄 유도체의 일수화물
US8802693B1 (en) 2011-03-09 2014-08-12 Abbvie Inc. Azaadamantane derivatives and methods of use
US20130317055A1 (en) * 2012-05-24 2013-11-28 Abbvie Inc. Neuronal nicotinic agonist and methods of use
WO2014164682A1 (en) 2013-03-12 2014-10-09 Abbvie Inc. Azaadamantane formate ester and process preparing azaadamantane derivatives
AR098747A1 (es) * 2013-12-13 2016-06-08 Allergan Inc Formas polimórficas de un compuesto similar a esteroides y métodos para su preparación y uso
EP3233087B1 (en) 2014-12-16 2019-10-02 Axovant Sciences GmbH Geminal substituted quinuclidine amide compounds as agonists of alpha-7 nicotinic acetylcholine receptors
AU2016274694A1 (en) 2015-06-10 2018-01-18 Axovant Sciences Gmbh Aminobenzisoxazole compounds as agonists of A7-nicotinic acetylcholine receptors
JP2018523707A (ja) 2015-08-12 2018-08-23 アクソバント サイエンシズ ゲーエムベーハー α７−ニコチン性アセチルコリン受容体のアゴニストとしてのジェミナル置換アミノベンゾイソオキサゾール化合物

Family Cites Families (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2514006A1 (fr) 1981-10-05 1983-04-08 Nativelle Sa Ets Acylamino-4 aza-1 adamantanes, procede pour leur preparation, et application en therapeutique
EP0088484A1 (en) 1982-02-04 1983-09-14 Fbc Limited Herbicidal thiadiazolyl N-aminoureas
GB8523211D0 (en) 1985-09-19 1985-10-23 Beecham Group Plc Compounds
EP0350130A3 (en) 1988-07-07 1991-07-10 Duphar International Research B.V New substituted 1,7-annelated 1h-indazoles
US5260303A (en) 1991-03-07 1993-11-09 G. D. Searle & Co. Imidazopyridines as serotonergic 5-HT3 antagonists
AU1752792A (en) 1991-03-08 1992-10-06 Rhone-Poulenc Rorer International (Holdings) Inc. Multicyclic tertiary amine polyaromatic squalene synthetase inhibitors
US5385912A (en) 1991-03-08 1995-01-31 Rhone-Poulenc Rorer Pharmaceuticals Inc. Multicyclic tertiary amine polyaromatic squalene synthase inhibitors
US5280028A (en) 1992-06-24 1994-01-18 G. D. Searle & Co. Benzimidazole compounds
US5434151A (en) 1992-08-24 1995-07-18 Cytomed, Inc. Compounds and methods for the treatment of disorders mediated by platelet activating factor or products of 5-lipoxygenase
US5840903A (en) 1992-07-27 1998-11-24 G. D. Searle & Co. 4-aminomethyl-1-azaadamantane derived benzamides
JP3235913B2 (ja) 1993-07-30 2001-12-04 エーザイ株式会社 アミノ安息香酸誘導体
US5399562A (en) 1994-02-04 1995-03-21 G. D. Searle & Co. Indolones useful as serotonergic agents
US5821370A (en) 1994-10-24 1998-10-13 Eli Lilly And Company Heterocyclic compounds and their preparation and use
US5852037A (en) 1995-11-13 1998-12-22 Eli Lilly And Company Method for treating anxiety
AU1128297A (en) 1995-12-06 1997-06-27 Eli Lilly And Company Composition for treating pain
WO1998027983A1 (en) 1996-12-20 1998-07-02 Novo Nordisk A/S A method of treating hypercholesterolemia and related disorders
US7732163B2 (en) 1997-08-21 2010-06-08 Board Of Trustees Of The University Of Arkansas Extracellular serine protease
US8236500B2 (en) 1997-10-23 2012-08-07 The United States Of America, As Represented By The Department Of Veterans Affairs Promoter variants of the alpha-7 nicotinic acetylcholine receptor
US6875606B1 (en) 1997-10-23 2005-04-05 The United States Of America As Represented By The Department Of Veterans Affairs Human α-7 nicotinic receptor promoter
ATE213246T1 (de) 1997-11-12 2002-02-15 2-phenyl-substituierte imidazotriazinone als phosphodiesterase inhibitoren
US5952339A (en) 1998-04-02 1999-09-14 Bencherif; Merouane Pharmaceutical compositions and methods of using nicotinic antagonists for treating a condition or disorder characterized by alteration in normal neurotransmitter release
US6057446A (en) 1998-04-02 2000-05-02 Crooks; Peter Anthony Certain 1-aza-tricyclo [3.3.1-13,7 ] decane compounds
ES2199561T3 (es) 1998-04-02 2004-02-16 Targacept, Inc. Derivados de azatriciclo(3.3.1.1)decano y composiciones farmaceuticas que los contienen.
US5986100A (en) 1998-04-02 1999-11-16 Crooks; Peter Anthony Pharmaceutical compositions and methods for use
US6277870B1 (en) 1998-05-04 2001-08-21 Astra Ab Use
WO1999062505A2 (en) 1998-06-01 1999-12-09 Ortho-Mcneil Pharmaceutical, Inc. Method for treating neurodegenerative disorders
US6093724A (en) * 1998-08-18 2000-07-25 Ucb, S.A. Muscarinic agonists and antagonists
ATE261448T1 (de) 1999-05-04 2004-03-15 Neurosearch As Heteroaryl diazabicycloalkene, deren herstellung und verwendung
US20010031771A1 (en) 1999-05-24 2001-10-18 Gary Maurice Dull Pharmaceutical compositions and methods for use
BR0011534A (pt) 1999-05-24 2002-02-26 Targacept Inc Alquilaminas aril substituìdas capazes de ativação de receptores colinérgicos nicotìnicos
WO2001040261A1 (en) 1999-12-01 2001-06-07 Ortho-Mcneil Pharmaceutical, Inc. Method of diagnosing neurodegenerative disease
AU2001257449A1 (en) 2000-05-01 2001-11-12 Targacept, Inc. Imaging of nicotinic acetylcholine receptor subtypes
AU2001265831B9 (en) 2000-07-04 2006-08-31 Neurosearch A/S Aryl and heteroaryl diazabicycloalkanes, their preparation and use
AUPR213700A0 (en) 2000-12-18 2001-01-25 Biota Scientific Management Pty Ltd Antiviral agents
US7112593B2 (en) 2001-03-27 2006-09-26 Eisai Co., Ltd. N-aryl-substituted cyclic amine derivative and medicine containing the same as active ingredient
US20030119060A1 (en) * 2001-08-10 2003-06-26 Desrosiers Peter J. Apparatuses and methods for creating and testing pre-formulations and systems for same
FR2832713B1 (fr) 2001-11-23 2004-02-13 Sanofi Synthelabo Derives de 4-(1,3,4-thiadiazol-2-yl)-1,4-diazabicyclo[3.2.2] nonane, leur preparation et leur application en therapeutique
CA2470567A1 (en) 2001-12-14 2003-06-26 Targacept, Inc. Methods and compositions for treatment of central nervous system disorders
US7300933B2 (en) 2002-05-07 2007-11-27 Neurosearch A/S Diazabicyclic biaryl derivatives
US7049374B2 (en) 2002-07-18 2006-05-23 Chevron U.S.A. Inc. Heterodiamondoids
MXPA05001702A (es) 2002-08-14 2005-04-19 Neurosearch As Derivados de quinuclidina novedosos y su uso.
US7030112B2 (en) 2003-03-25 2006-04-18 Bristol-Myers Squibb Company Pyrrolopyridazine compounds and methods of use thereof for the treatment of proliferative disorders
WO2004091646A2 (en) 2003-04-16 2004-10-28 Applied Research Systems Ars Holding, N.V. Use of slurp-1 for treating diseases related to acetylcholine receptors dysfunction
US7202363B2 (en) 2003-07-24 2007-04-10 Abbott Laboratories Thienopyridine and furopyridine kinase inhibitors
JP5010917B2 (ja) 2003-08-29 2012-08-29 エグゼリクシス， インコーポレイテッド ｃ−Ｋｉｔ調節因子および使用方法
US20050065178A1 (en) 2003-09-19 2005-03-24 Anwer Basha Substituted diazabicycloakane derivatives
US7399765B2 (en) 2003-09-19 2008-07-15 Abbott Laboratories Substituted diazabicycloalkane derivatives
TWI331154B (en) 2003-11-12 2010-10-01 Solvay Pharm Gmbh Novel 17-hydroxysteroid dehydrogenase type i inhibitors
WO2006065233A1 (en) 2004-12-10 2006-06-22 Abbott Laboratories Fused bicycloheterocycle substituted quinuclidine derivatives
JP2005232071A (ja) 2004-02-19 2005-09-02 Kanto Chem Co Inc ピラゾール誘導体
MXPA06012595A (es) 2004-04-29 2007-05-09 Abbott Lab Analogos de amino-tetrazoles y metodos de uso.
EA014419B1 (ru) 2004-05-24 2010-12-30 Эмджен Инк. 5,5-дизамещённые-2-амино-4-тиазолидиноны и способ их получения, фармацевтическая композиция и способ лечения
AR049401A1 (es) 2004-06-18 2006-07-26 Novartis Ag Aza-biciclononanos
FR2872165B1 (fr) 2004-06-24 2006-09-22 Sod Conseils Rech Applic Nouveaux derives de pyrimido-benzimidazole
GB0415746D0 (en) 2004-07-14 2004-08-18 Novartis Ag Organic compounds
CN101087756B (zh) 2004-07-23 2011-04-06 纽阿达有限责任公司 肽酶抑制剂
EP2404605B1 (en) 2004-08-25 2015-04-22 Essentialis, Inc. Pharmaceutical formulations of potassium ATP channel openers and uses thereof
EP1802616B1 (en) 2004-10-15 2011-01-12 NeuroSearch A/S Novel azabicyclic aryl derivatives and their medical use
WO2006045716A1 (en) 2004-10-20 2006-05-04 Neurosearch A/S Novel diazabicyclic aryl derivatives and their medical use
WO2007024391A2 (en) 2005-07-22 2007-03-01 The Board Of Trustees Of The Leland Stanford Junior University Light-activated cation channel and uses thereof
US9274099B2 (en) 2005-07-22 2016-03-01 The Board Of Trustees Of The Leland Stanford Junior University Screening test drugs to identify their effects on cell membrane voltage-gated ion channel
US7897766B2 (en) 2005-09-23 2011-03-01 Abbott Laboratories Amino-aza-adamantane derivatives and methods of use
NZ567048A (en) 2005-12-06 2010-12-24 Neurosearch As Novel diazabicyclic aryl derivatives and their medical use
US20090291976A1 (en) 2006-06-27 2009-11-26 Peter Andrew Ferchmin Neuronal circuit-dependent neuroprotection by interaction between nicotinic receptors
FR2905009A1 (fr) 2006-08-18 2008-02-22 Servier Lab Methode de criblage de composes aux proprietes anti-amyloide
US20100234349A1 (en) 2006-09-04 2010-09-16 Olsen Gunnar M Pharmaceutical combinations of a nicotine receptor modulator and a cognitive enhancer
KR20090087009A (ko) 2006-10-27 2009-08-14 메디베이션 뉴롤로지 인코퍼레이티드 아이.에이. 다임본 및 도레페질을 사용하여 알츠하이머 병을 치료하기 위한 조합 요법
TW200827346A (en) 2006-11-03 2008-07-01 Astrazeneca Ab Chemical compounds
US8314119B2 (en) 2006-11-06 2012-11-20 Abbvie Inc. Azaadamantane derivatives and methods of use
CN101541792A (zh) * 2006-11-06 2009-09-23 艾博特公司 氮杂金刚烷衍生物和应用方法
RU2441868C2 (ru) 2007-02-09 2012-02-10 Астеллас Фарма Инк. Аза-кольцевое соединение с внутренним мостиком
WO2008106694A2 (en) 2007-03-01 2008-09-04 The Board Of Trustees Of The Leland Stanford Junior University Systems, methods and compositions for optical stimulation of target cells
WO2008112177A2 (en) 2007-03-08 2008-09-18 Genizon Biosciences, Inc. Genemap of the human genes associated with schizophrenia
MX2009010174A (es) 2007-03-23 2009-10-12 Abbott Lab Derivados de aza-adamantano ester y carbamato y metodos de uso de los mismos.
ES2521494T3 (es) 2007-04-02 2014-11-12 Parkinson's Institute Métodos y composiciones para la reducción de los efectos secundarios de tratamientos terapéuticos
WO2009017454A1 (en) 2007-07-30 2009-02-05 Astrazeneca Ab New therapeutic combination of a gsk3 inhibitor and an a7-nicotinic agonist 960
SA08290475B1 (ar) 2007-08-02 2013-06-22 Targacept Inc (2s، 3r)-n-(2-((3-بيردينيل)ميثيل)-1-آزا بيسيكلو[2، 2، 2]أوكت-3-يل)بنزو فيوران-2-كربوكساميد، وصور أملاحه الجديدة وطرق استخدامه
US8697722B2 (en) 2007-11-02 2014-04-15 Sri International Nicotinic acetylcholine receptor modulators
WO2009058120A1 (en) 2007-11-02 2009-05-07 Sri International Nicotinic acetylcholine receptor modulators
US8273889B2 (en) 2007-11-20 2012-09-25 Nissan Chemical Industries, Ltd. Method for producing 2-azaadamantane
DE102007058504A1 (de) 2007-12-05 2009-07-09 Acino Ag Transdermales therapeutisches System mit einem Gehalt an einem Modulator für nikotinische Acetylcholinrezeptoren (nAChR)
EP2254598B1 (en) 2008-02-13 2013-07-10 Targacept, Inc. Combination of alpha 7 nicotinic agonists and antipsychotics
US20090239901A1 (en) 2008-03-19 2009-09-24 Merouane Bencherif Method and compositions for treatment of cerebral malaria
US20110098312A1 (en) 2008-05-12 2011-04-28 Targacept ,Inc Methods for preventing the development of retinopathy by the oral administration of nnr ligands
FR2931677B1 (fr) 2008-06-02 2010-08-20 Sanofi Aventis Association d'un agoniste partiel des recepteurs nicotiniques et d'un inhibiteur d'acetylcholinesterase, composition la contenant et son utilisation dans le traitement des troubles cognitifs
CA2727141A1 (en) 2008-06-13 2009-12-17 Centre For Addiction And Mental Health Compositions and methods for modulating nicotinic/nmda receptor function
WO2010030887A1 (en) 2008-09-11 2010-03-18 Catholic Healthcare West Nicotinic attenuation of cns inflammation and autoimmunity
US8435762B2 (en) 2008-10-09 2013-05-07 Howard Hughes Medical Institute Chimeric ligand-gated ion channels and methods of use thereof
WO2010056622A1 (en) 2008-11-11 2010-05-20 Targacept, Inc. TREATMENT WITH ALPHA α7-SELECTIVE LIGANDS
WO2010088400A1 (en) 2009-01-28 2010-08-05 Catholic Healthcare West Methods of diagnosing and treating neurodegenerative diseases
AU2010278730A1 (en) 2009-07-31 2012-03-01 Biocryst Pharmaceuticals, Inc. Pyrrolo [1, 2-b] pyridazine derivatives as janus kinase inhibitors
EP2467131A4 (en) 2009-08-21 2014-02-19 Univ Florida FORMULATIONS OF ANABASEIN COMPOUNDS WITH TAXED RELEASE AND THEIR USE
WO2011044537A2 (en) 2009-10-09 2011-04-14 Afraxis, Inc. Methods for treating alzheimer's disease
WO2011058582A1 (en) 2009-11-16 2011-05-19 Orchid Research Laboratories Ltd. Histone deacetylase inhibitors for the treatment of fungal infections
KR20130108586A (ko) 2010-09-23 2013-10-04 애브비 인코포레이티드 아자아다만탄 유도체의 일수화물
EP2441755A1 (en) 2010-09-30 2012-04-18 Almirall, S.A. Pyridine- and isoquinoline-derivatives as Syk and JAK kinase inhibitors
WO2012059932A1 (en) 2010-11-01 2012-05-10 Aurigene Discovery Technologies Limited 2, 4 -diaminopyrimidine derivatives as protein kinase inhibitors

Also Published As

Publication number Publication date
MX2013003344A (es) 2013-06-28
ECSP13012575A (es) 2013-07-31
CL2013000756A1 (es) 2013-07-12
SG2014013460A (en) 2014-09-26
DOP2013000064A (es) 2013-07-15
AU2011305462A1 (en) 2013-03-21
BR112013005434A2 (pt) 2016-06-07
CN103180321A (zh) 2013-06-26
KR20130108586A (ko) 2013-10-04
US9464078B2 (en) 2016-10-11
RU2013118560A (ru) 2014-10-27
EP2619205A1 (en) 2013-07-31
GT201300064A (es) 2014-07-11
TW201626996A (zh) 2016-08-01
CL2014000651A1 (es) 2014-09-05
NZ609761A (en) 2015-10-30
RU2579121C2 (ru) 2016-03-27
CA2809675A1 (en) 2012-03-29
CR20130169A (es) 2013-06-12
SG188307A1 (en) 2013-04-30
JP2013537912A (ja) 2013-10-07
AR083100A1 (es) 2013-01-30
AU2011305462B2 (en) 2015-11-26
BR122014023207A2 (pt) 2019-05-28
CR20130594A (es) 2014-01-31
EP2619205B1 (en) 2017-05-17
US20150239882A1 (en) 2015-08-27
RU2016105706A (ru) 2018-11-22
CO6720965A2 (es) 2013-07-31
UY33628A (es) 2012-03-30
US20120245195A1 (en) 2012-09-27
CN106074548A (zh) 2016-11-09
UA110802C2 (uk) 2016-02-25
PE20131394A1 (es) 2014-01-11
JP2017039764A (ja) 2017-02-23
NZ707955A (en) 2016-03-31
WO2012040404A1 (en) 2012-03-29
TW201212914A (en) 2012-04-01

Similar Documents

Publication Publication Date Title
DOP2013000249A (es) Monohidrato de derivados de aza-adamantano
CR20120277A (es) Una forma cristalina y amorfa de genz 112638 hemitartrato como inhibidores de glucosilceramida sintasa
CR20140231A (es) Derivados de ácido benzotiazol-6-il acético y su uso para tratar una infección por vih
MX2010012298A (es) Activadores de glucocinasa.
PA8827101A1 (es) Derivados de indazoles sustituidos con fenilo o piridinilo
CL2012003491A1 (es) Compuesto derivado de dihidropirrol sustituidos; proceso para preparar dichos derivados en forma estereoselectiva.
CR20140546A (es) Forma cristalina a de 1,5-dimetil-6-tioxo-3- (2,2,7-trifluoro- 3-oxo-4- (prop-2-inil)-3,4-dihidro -2h-benzo [b] [1,4] oxazin-6-il)-1,3,5- triazinan-2,4-diona
CL2017001100A1 (es) Nuevas triazolo[4,5-d]pirimidinas
CL2013001221A1 (es) Compuesto clorhidrato de (4a-r, 9a-s)-1-(1h-benzoimidazol-5-carbonil-2,3,4,4a,9,9a-hexahidro-1 h-inden[2,1-b] piridin-6-carbonitrilo y sus formas cristalinas i y ii, inhibidores de hsd 1; composicion farmaceutica; metodo para producir la forma cristalina i del compuesto; metodo para producir la forma cristalina ii del compuesto.
MX2014010433A (es) Nueva forma cristalina de sulfato de sitagliptina.
AR093738A1 (es) Formas solidas que comprenden inhibidores de ns5a de hcv, sus composiciones y sus usos
IN2014DN10669A (es)
CL2011003123A1 (es) Compuestos derivados de ciclopentanamida sustituidos; composicion farmaceutica; proceso de obtencion; y uso en el tratamiento o la profilaxis de la diabetes, aterosclerosis, entre otras.
GB201020397D0 (en) Compounds
MX2015016766A (es) Nuevos derivados de tetrazolona.
NI200900154A (es) Nuevos procedimiento de obtención de la forma cristalina v de la agomelatina
CR9613S (es) Contenedor
AR089929A1 (es) Proceso para manufacturar un derivado de naftiridina
AR098614A1 (es) Compuesto para el tratamiento de hipoglicemia severa
WO2014145035A8 (en) Methods of making cancer compositions
CO7200259A2 (es) Nuevos derivados de piridina
AR095353A1 (es) Compuesto
ECSP11011150A (es) Derivados de arilciclopropilacetamida útiles como activadores de glucoquinasa
CL2012000350A1 (es) Combinacion farmaceutica que comprende un compuesto derivado de bifenilamida y un agente inhibidor de bcr-abl seleccionado de nilotinib; composicion farmaceutica; y uso de la combinacion para el tratamiento de leucemia positiva a bcr-abl.
CY1116535T1 (el) Μεθοδος συνθεσης παραγωγων της 7,8-διμεθοξυ-1,3-διυδρο-2η-3-βενζαζεπιν-2-ονης και εφαρμογη στην συνθεση της ιβαμπραδινης